Q2 FY2026 EarningsQ2 FY26 revenue of $119.6M beat consensus by 7.8%, driven by a 46% YoY surge in net product sales. However, GAAP EPS was a significant miss at -$1.14 vs. $0.49 expected, primarily due to a $161M non-cash fair value write-down of equity investments (largely Armata Pharmaceuticals). IST U.S. sales guidance for 2026 remains at $150M+, while the launch of Nortiva Bio adds a new long-acting drug delivery platform to the pipeline.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Innoviva(INVA) the Revenue is 119.59 M (+19.25%), Beat estimate;the EBIT is 50.86 M (+4.32%), Miss estimate;the EPS is -1.14 (-248.1%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.12B19.25%
0.11B10.67%
+0.01B8.58%
EBITMiss expectations
0.05B4.32%
0.05B6.52%
-0.00B2.20%
EPSMiss expectations
-1.14248.05%
0.487536.69%
-1.6275211.36%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf